Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical vs Injection of Botox for Non-Infectious Chronic Rhinosinusitis
NCT04572516Phase 3Completed
- Sponsor
- Benha University
- Start
- May 2020
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Onabotulinumtoxina + hydrogel in chronic rhinosinusitis (CRS) (2 arms), sponsored by Benha University. Primary endpoint: Total Nasal Symptom Score at 2 months. Started May 2020; status: completed.
02
Drugs
Onabotulinumtoxina + hydrogel
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT04572516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572516.